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Abstract
Background: Since 1998, Italian law requires serological screen-
ing for toxoplasmosis by the thirteenth week of pregnancy, and 
seronegative women should undergo further checks every 30 - 40 
days until delivery (a total of 5 - 7 screenings). This is an improve-
ment of the previous law which foresaw three free tests (one by the 
end of the third month, one in the fifth, and one in the ninth month 
of pregnancy). The aim of this study was to assess the implementa-
tion, in an urban area of Northern Italy, of the 1998 law about 10 
years after its entry into force. 
Methods: Of the 4,694 women who initiated and completed a preg-
nancy in the period 2006 - 2008, we recorded the trimester of preg-
nancy in which they underwent their first screening, the total and 
average number of screenings during pregnancy, and the trimester 
distribution of the screenings.
Results: A  total  of  84.1%  of  the  women  underwent  their  first 
screening during the first trimester. The negative cases underwent 
an average of 3.7 screenings during pregnancy, with 34.9% under-
going five or more. Sixty percent of the women underwent at least 
one screening per trimester.
Conclusions: Our data indicates active screening during the first 
trimester, but fewer screenings than required by law during preg-
nancy as a whole. Therefore further efforts are needed to improve 
screening implementation.
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Introduction
Infection  due  to  Toxoplasma  gondii  is  one  of  the  major 
causes of congenital infection leading to severe fetal damage 
[1]. It is estimated that congenital toxoplasmosis affects 1 
- 10/10,000 babies in Europe [2], but its incidence and sever-
ity vary depending on the trimester in which the infection is 
contracted: the frequency of transmission increases propor-
tionately with gestational age, whereas severity of infection 
decreases [3-5]. 
In addition to health education campaigns, preventive 
screening programmes have been proposed for pre-pregnant 
and pregnant women, as well as newborns, but depending 
on the prevalence of infection in the population, cost/benefit 
questions mean that serological screening during pregnancy 
is not recommended in some countries (Britain, Holland, 
Norway and USA) [6-9], and is implemented in different 
ways in others such as France, Belgium, Switzerland, Ger-
many and Austria [10-12]. In Italy, where the reported anti-
body prevalence varies from 21% to 48% [13-18], the law of 
1995 (Official Gazette No. 87, 13/04/95) foresaw three free 
tests for Toxoplasma antibodies (one by the end of the third 
month, one in the fifth, and one in the ninth month of preg-
nancy). Since 1998 (Official Gazette No. 245, 20/10/98), 
there has laid down a protocol based on an initial screening 
by the end of the 13th week, and the further screenings of 
seronegative women every 30 - 40 days until delivery (a total 
of 5 - 7). Implementing such a demanding screening pro-
gram requires the full cooperation of general practitioners 
and women, as well as an efficient organisation capable of 
providing easy access for sampling and rapid results. Fur-
thermore, it has been shown that 30 - 35% of seronegative 
women do not complete the follow-up during pregnancy, re-
gardless of whether screening is formally recommended or 
not [19, 20]. 
The aim of this study was to assess the implementation 
of serological Toxoplasma antibody screening during preg-
nancy in an urban area of Northern Italy about 10 years after 
entry into force of 1998 law.
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Materials and Methods
We  retrospectively  reviewed  the  data  concerning  4,694 
women (mean age 31.4 years; range 15 - 49 years) resident 
in the urban area of Legnano, near Milan (Northern Italy), 
who had started and concluded a pregnancy in the period 
2006 - 2008, when women underwent serological screening 
for antibodies to Toxoplasma IgG and IgM ELISA (Enzyme-
Linked  ImmunoSorbent  Assay)  (ETI-TOXOK-G-PLUS, 
ETI-TOXOK reverse M-PLUS; Dia Sorin, Saluggia, Italy). 
The IgG cut-off value was 15 IU/m; in the case of IgM, sam-
ples with a D.O. sample/D.O. cut off value of no less than 1 
were considered positive. 
The  ELISA  IgM-positive  samples  were  subsequently 
tested by means of ELFA (Enzyme-Linked Fluorescent As-
say) (VIDAS Toxo IgM, BioMérieux, Lyon, France); the 
samples with an index of no less than 0.65 were considered 
positive, and those with an index of 0.55 - 0.65 were con-
sidered borderline. When possible, IgG avidity was deter-
mined in the ELISA IgM-positive samples (VIDAS Toxo 
IgG avidity, BioMerieux, Lyon, France), and was classified 
low if the index was less than 0.200, borderline if it was no 
less than 0.200 but less than 0.300, and high if it was no less 
than 0.300. The IgM-positive women were sent to Reference 
Centres.
The considered data were the trimester of pregnancy in 
Table 1. Prevalence of Anti-Toxoplasma Antibodies by Trimester of First Screening
 
I trimester
(group 1)
 
II trimester
(group 2)
 
III trimester
(group 3)
 
Total
Anti-Toxoplasma
antibodies
No. % (95% CI) No. % (95% CI) No. % (95% CI) No. % (95% CI)
 
IgG neg/IgM neg
 
2975
 
75.3
(73.95-76.65)
 
386
 
89.6
(86.72-92.48)
 
273
 
86.9
(83.17-90.63)
 
3634
 
77.4
(76.20-78.60)
IgG pos/IgM neg 893 22.6
(21.29-23.90)
44 10.2
(7.34-13.06)
37 11.8
(8.23-15.37)
974 20.7
(19.54-21.86)
IgG neg/IgM pos 12 0.3
(0.13-0.47)
0 0
(0.00-0.00)
2 0.6
(0.00-1.45)
14 0.3
(0.14-0.46)
IgG pos/IgM pos 69 1.7
(1.30-2.10)
1 0.2
(0.00-0.62)
2 0.6
(0.00-1.45)
72 1.5
(1.15-1.85)
Total 3949 431 314 4694
CI: Confidence Interval
 
Trimester of first 
screening
No. of seronegative 
women
 
Average number of 
screenings (range)
 
No. of screenings
1 2 - 4 ≥ 5
 
1
 
2975
 
4.1 (1 - 10)
 
313 (10.5%)
 
1415 (47.6%)
 
1247 (41.9%)
2 386 2.3 (1 - 6) 118 (30.6%) 247 (64.0%) 21 (5.4%)
3 273 1.2 (1 - 3) 230 (84.2%) 43 (15.8%) -
Total 3634 3.7 (1 - 10) 661 (18.2%) 1705 (46.9%) 1268 (34.9%)
Table 2. Average and Total Number of Screenings of Pregnant Seronegative Women by the Trimester of the 
First Screening
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which the women underwent their first screening, the total 
and average number of screenings during pregnancy, and the 
trimester distribution of the screenings.
Results
Of the 4,694 women involved in the study, 3,949 underwent 
their first screening in the first trimester (84.1% = group 1), 
431 in the second (9.2% = group 2), and 314 in the third 
(6.7% = group 3). 
At the first screening, a total of 3,634 women (77.4%) 
were negative for both anti-Toxoplasma IgG and IgM an-
tibodies, 974 (20.7%) were IgG positive and IgM negative, 
and 86 (1.8%) were IgM positive, of whom 14 (0.3%) were 
IgG negative and 72 (1.5%) IgG positive. Table 1 shows the 
seroprevalence of antibodies in relation to the trimester of 
the first screening. 
Of  the  86  ELISA  IgM-positive  samples,  59  (68.6%) 
were positive or borderline at ELFA: four IgG- negative and 
55 IgG-positive samples, in which IgG avidity was low in 
six cases (10.9%), borderline in four (7.3%) and high in 45 
(81.8%). Fourteen cases were considered primary infections: 
four IgG negative and IgM positive (confirmed by ELFA), 
and 10 both IgG and IgM positive (confirmed by ELFA) with 
low or borderline IgG avidity. The 3,634 seronegative wom-
en underwent an average of 3.7 screenings (range 1 - 10); 
only 1268 (34.9%) underwent five or more as laid down in 
the Ministerial Decree (Table 2), but 2,181 (60.0%) under-
went at least one screening per trimester (Table 3). 
Of the 2,975 seronegative women who underwent their 
first  screening  during  the  first  trimester  (group  1),  2,481 
(83.4%) underwent at least one screening in the second, and 
2,322 (78.1%) in the third. Three seroconversions were ob-
served in the third trimester (two IgG negative and ELISA 
and ELFA IgM positive, and one ELISA and ELFA IgM 
positive and IgG positive with low avidity) after respectively 
32, 37 and 40 weeks of pregnancy (all were negative in the 
second trimester) (Table 4). There were no seroconversions 
in group 2 or 3. 
Table 5 shows the 17 primary infections (including se-
roconversions) by the trimester in which IgM appeared: 11 
ELISA/ELFA IgM positive and IgG positive with low or 
borderline avidity, and six ELISA/ELFA IgM positive and 
IgG negative.
 
Screenings
 
No. of  
women
 
% (95% CI)
 
Only I trimester
 
353
 
9.7 (8.74 - 10.66)
I trimester + II trimester 300 8.3 (7.40 - 9.20)
I trimester + II trimester + 
III trimester
2181 60.0 (58.41 - 
61.59)
I trimester + III trimester 141 3.9 (3.27 - 4.53)
Only II trimester 138 3.8 (3.18 - 4.42)
II trimester + III trimester 248 6.8 (5.98 - 7.62)
Only III trimester 273 7.5 (6.64 - 8.36)
Total 3634
Table 3. Screenings of Seronegative Women by Trimes-
ter of Pregnancy
CI: Confidence Interval
Anti-Toxoplasma IgM antibodies
Weeks of pregnancy
Case 13 18 23 27 32 37 40
 
1
 
Neg
 
Neg
 
-
 
Neg
 
Pos
 
-
 
-
2 Neg Neg Neg - - Pos -
3 Neg Neg - - - - Pos
Table 4. Cases of Seroconversion by Week of Pregnancy
I trimester II trimester III trimester Total
 
IgM+ IgG+ (low or borderline avidity)
 
9 (81.8%)
 
1 (9.1%)
 
1 (9.1%)*
 
11
IgM+ IgG- 3 (50%) 0 3 (50%)** 6
Total 12 (70.6%) 1 (5.9%) 4 (23.5%) 17
Table 5. Primary Infections by the Trimester in Which IgM Was Detected
*seroconversion 
**two seroconversions
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Discussion
  
The severity of congenital Toxoplasma gondii infection has 
prompted  some  countries  to  implement  antibody  screen-
ing campaigns to detect possible infections at risk of being 
transmitted to the fetus. Current Italian legislation indicates 
a protocol for laboratory tests including the search for anti-
Toxoplasma antibodies at the beginning of pregnancy (if 
possible before the 13th week) and, in the case of IgG nega-
tivity, repeat tests every 30 - 40 days until delivery for a total 
of 5 - 7 screenings. This protocol is particularly demanding 
and requires the full cooperation of general practitioners and 
patients. 
This  study  showed  that  the  vast  majority  of  women 
resident  in  our  area  began  monitoring  by  the  end  of  the 
first trimester, which is very important because it is easier 
to assess and manage a possible acute infection in this pe-
riod and that is when most of our cases of primary infection 
occurred. However, about 16% of the women delayed the 
first screening until after the first trimester, and it is these to 
whom efforts to improve screening should be directed, not 
least because two of the women who were first screened in 
the third trimester were IgM positive and showed high IgG 
avidity. As no previous data were available, it is impossible 
to distinguish an infection occurring before conception from 
an acute infection occurring in the first trimester. 
About one-third of the seronegative women underwent 
subsequent screening as laid down in the Ministerial Decree, 
which suggests that a protocol of 5 - 7 samples may be very 
demanding as pregnant women face a number of difficulties, 
including a fear of blood sampling, logistical difficulties, 
taking time off work, etc. Furthermore, it is possible that 
their general practitioners may not have been aware of the 
change in legislation, and may have still been operating on 
the basis of the previous legislation that required only three 
screenings: in fact if we consider the seronegative women 
who underwent screening at least once per trimester, the 
proportion of women who covered the entire pregnancy was 
60%, and almost 80% of those who began the follow-up in 
the first trimester attended at least one further screenings in 
both the second and the third trimester.
But if the coverage of pregnancy with only three screen-
ings  is  very  satisfactory,  the  current  protocol  whit  5  -  7 
screenings at intervals of 30 - 40 days would reveal early se-
roconversion and allow timely therapeutic measures. From 
this perspective, the results of this study have to be consid-
ered disappointing. The three seroconversions were all de-
tected in the third trimester, and the interval between the last 
negative test and the first positive test was 35 days in only 
one case; in the other two, it was respectively 98 and 154 
days.
Unfortunately, we have no data regarding the transmis-
sion of infection to the fetus because the IgM-positive wom-
en were all referred for further investigations to Reference 
Centres throughout the area.
In conclusion, the results of this study show that the 
current management of screening is sufficiently active in re-
cruiting women within the first trimester of pregnancy, but 
weaker in following up seronegative cases as indicated by 
the Ministerial Decree in force. Further studies are necessary 
to understand exactly what are the critical points in terms 
of compliance on which to focus the efforts to improve the 
screening.
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